Details

Autor(en) / Beteiligte

• Zhang, Danmei
• Dorman, Klara
• Heinrich, Kathrin
• Weiss, Lena
• Boukovala, Myrto
• Haas, Michael
• Greif, Philipp A.
• Ziemann, Frank
• Beyer, Georg
• Roessler, Daniel
• Goni, Elisabetta
• Renz, Bernhard
• D’Haese, Jan G.
• Kunz, Wolfgang G.
• Seidensticker, Max
• Corradini, Stefanie
• Niyazi, Maximilian
• Ormanns, Steffen
• Kumbrink, Jörg
• Jung, Andreas
• Mock, Andreas
• Rudelius, Martina
• Klauschen, Frederick
• Werner, Jens
• Mayerle, Julia
• von Bergwelt-Baildon, Michael
• Boeck, Stefan
• Heinemann, Volker
• Westphalen, C. Benedikt

Titel

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich

Ist Teil von

• Targeted oncology, 2023-09, Vol.18 (5), p.767-776

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2023

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Background and Objective With the rising importance of precision oncology in biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe the clinical and molecular characteristics of patients with BTC who underwent comprehensive genomic profiling (CGP) and were discussed in the CCCMunich LMU molecular tumor board (MTB). Patients and Methods In this single-center observational study, we included BTC patients with intrahepatic cholangiocarcinoma (iCCA), extrahepatic CCA (eCCA), and gallbladder cancer (GB), who had been discussed in the institutional MTB from May 29, 2017, to July 25, 2022. Patients were followed up until 31 January 2023. Data were retrospectively collected by review of medical charts, and MTB recommendation. Results In total, 153 cases were registered to the MTB with a median follow-up of 15 months. Testing was successful in 81.7% of the patients. CGP detected targetable alterations in 35.3% of our BTC patients (most commonly ARID1A/ERBB2/IDH1/PIK3CA/BRAF -mutations and FGFR2 -fusions ). Recommendations for molecularly guided therapy were given in 46.4%. Of those, treatment implementation of targeted therapy followed in 19.4%. In patients receiving the recommended treatment, response rate was 57% and median overall survival was 19 months (vs 8 months in the untreated cohort). The progression-free survival ratio of 1.45 suggest a clinical benefit of molecularly guided treatment. Conclusions In line with previous work, our series demonstrates feasibility and clinical utility of comprehensive genomic profiling in BTC patients. With the growing number of targeted agents with clinical activity in BTC, CGP should become standard of care in the management of this group of patients.